Breyanzi (lisocabtagene maraleucel)

pCPA File Number: 21939

Negotiation Status:

Concluded with an LOI

Indication(s):

Adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma

Sponsor/Manufacturer:

Celgene Inc.

CDA-AMC Project Number:

PG0258-000

pCPA Engagement Letter Issued:

2023-01-20

Negotiation Process Concluded:

2023-12-12